We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Allarity Therapeutics, Inc. (ALLR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Allarity Therapeutics, Inc. is one of 885 companies in the Medical group. The Medical group currently sits at #9 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Allarity Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ALLR's full-year earnings has moved 5.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALLR has moved about 32.4% on a year-to-date basis. In comparison, Medical companies have returned an average of -5.8%. This shows that Allarity Therapeutics, Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Alterity Therapeutics Limited - Sponsored ADR (ATHE - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 58.4%.
The consensus estimate for Alterity Therapeutics Limited - Sponsored ADR's current year EPS has increased 31.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Allarity Therapeutics, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 431 individual companies and currently sits at #149 in the Zacks Industry Rank. On average, this group has lost an average of 1.7% so far this year, meaning that ALLR is performing better in terms of year-to-date returns. Alterity Therapeutics Limited - Sponsored ADR is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Allarity Therapeutics, Inc. and Alterity Therapeutics Limited - Sponsored ADR as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Allarity Therapeutics, Inc. (ALLR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Allarity Therapeutics, Inc. is one of 885 companies in the Medical group. The Medical group currently sits at #9 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Allarity Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ALLR's full-year earnings has moved 5.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALLR has moved about 32.4% on a year-to-date basis. In comparison, Medical companies have returned an average of -5.8%. This shows that Allarity Therapeutics, Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Alterity Therapeutics Limited - Sponsored ADR (ATHE - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 58.4%.
The consensus estimate for Alterity Therapeutics Limited - Sponsored ADR's current year EPS has increased 31.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Allarity Therapeutics, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 431 individual companies and currently sits at #149 in the Zacks Industry Rank. On average, this group has lost an average of 1.7% so far this year, meaning that ALLR is performing better in terms of year-to-date returns. Alterity Therapeutics Limited - Sponsored ADR is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Allarity Therapeutics, Inc. and Alterity Therapeutics Limited - Sponsored ADR as they could maintain their solid performance.